Literature DB >> 21997572

Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.

E Scherman, S Malak, C Perot, N C Gorin, M T Rubio, F Isnard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21997572     DOI： 10.1038/leu.2011.284

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

Authors:  G Visani; F Ferrara; F Di Raimondo; F Loscocco; G Sparaventi; S Paolini; F Fuligni; A Gazzola; M Rossi; M A Laginestra; M R Caraci; C Riccardi; M Rocchi; A Visani; S A Pileri; P P Piccaluga; A Isidori
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

2.  Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

Authors:  Courtney D DiNardo; Naval Daver; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Marina Konopleva; Naveen Pemmaraju; Hui Yang; Sherry Pierce; William Wierda; Carlos Bueso-Ramos; Keyur P Patel; Jorge E Cortes; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Lancet Haematol       Date:  2014-12-22       Impact factor: 18.959

3.  Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Authors:  Daniel A Pollyea; James Zehnder; Steve Coutre; Jason R Gotlib; Leonel Gallegos; Omar Abdel-Wahab; Peter Greenberg; Bing Zhang; Michaela Liedtke; Caroline Berube; Ross Levine; Beverly S Mitchell; Bruno C Medeiros
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 4.  Expanding role of lenalidomide in hematologic malignancies.

Authors:  Nilanjan Ghosh; Michael R Grunwald; Omotayo Fasan; Manisha Bhutani
Journal:  Cancer Manag Res       Date:  2015-05-02       Impact factor: 3.989

Review 5.  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Authors:  Abdallah Abou Zahr; Ehab Saad Aldin; Rami S Komrokji; Amer M Zeidan
Journal:  J Blood Med       Date:  2014-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.